Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY:BSX)

62.25 -0.50 (-0.80%)
Streaming Delayed Price Updated: 9:51 AM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Boston Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
SNAP, BSX, PYPL Stocks Hit 52-Week Lows — But Refuse To Stay Down After-Hours ↗
Via Stocktwits
News headline image
Stock Market Today, Feb. 4: Boston Scientific Plunges After Cautious 2026 Guidance Disappoints Investors ↗
Today, Feb. 4, 2026, investors are weighing Boston Scientific’s guidance against new deals and its long-term margin path. 
Via The Motley Fool
Topics Earnings Stocks
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Why Boston Scientific Stock Plummeted Today ↗
I'll be keeping a close eye on Boston Scientific stock following the market's peculiar reaction to its solid earnings report. 
Via The Motley Fool
BSX Stock Tumbles Pre-Market On Softer 2026 Sales Growth Forecast ↗
Via Stocktwits
Boston Scientific Corp (NYSE:BSX) Stock Plummets 9% Despite Mixed Q4 2025 Earnings ↗
Via Chartmill
News headline image
Boston Scientific (BSX) Earnings Transcript ↗
Boston Scientific (BSX) Earnings Transcript 
Via The Motley Fool
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Why Boston Scientific (BSX) Shares Are Getting Obliterated Today
Shares of medical device company Boston Scientific (NYSE:BSX) fell 13.9% in the afternoon session after the company reported fourth-quarter 2025 results that beat Wall Street estimates but provided a... 
Via StockStory
Gapping S&P500 stocks in Wednesday's session ↗
Via Chartmill
News headline image
Boston Scientific Stock Hits 52-Week Low On Soft 2026 Outlook ↗
Boston Scientific Corporation (NYSE: BSX) reported Q4 2025 revenues of $5.29B, beating management guidance and consensus estimate. 
Via Benzinga
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Boston Scientific (NYSE:BSX) Reports Q4 CY2025 In Line With Expectations
Medical device company Boston Scientific (NYSE:BSX) met Wall Streets revenue expectations in Q4 CY2025, with sales up 15.9% year on year to $5.29 billion. The company expects next quarter’s revenue to... 
Via StockStory
News headline image
Earnings To Watch: Boston Scientific (BSX) Reports Q4 Results Tomorrow
Medical device company Boston Scientific (NYSE:BSX) will be announcing earnings results this Wednesday before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
3 Market-Beating Stocks with Exciting Potential
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends... 
Via StockStory
News headline image
Boston Scientific to Acquire Penumbra for $14.5 Billion in Massive MedTech Consolidation
MARLBOROUGH, Mass. — In a move that has sent shockwaves through the medical technology landscape, Boston Scientific (NYSE: BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra... 
Via MarketMinute
News headline image
The $14.5 Billion Clot-Bust: Boston Scientific’s Bold Bet on Penumbra Signals a New Era of Medtech Giants
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN)... 
Via MarketMinute
News headline image
S&P 500 Hits Record Highs as Tech Earnings Ignite Market Rally
The U.S. stock market reached a historic milestone on January 27, 2026, as the S&P 500 (NYSEARCA:SPY) climbed to a fresh all-time high of 6,980.75, tantalizingly close to the psychologically... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
The Great Consolidation: US M&A Values Double as AI and Bio-Pharma Spark $2 Trillion Surge
As of January 26, 2026, the American corporate landscape is undergoing its most radical transformation in a generation. Following a two-year period of high-interest-rate hibernation, the United States... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles
Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth
NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an... 
Via MarketMinute
Topics Earnings Economy
News headline image
The Titan’s Balance: Johnson & Johnson Reaches Record Highs Amidst Legal Hurdles and Med-Tech Transformation
As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On... 
Via MarketMinute
Topics Bankruptcy Lawsuit World Trade
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
From Brodsky & Smith LLC
Via GlobeNewswire
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.